Here are five notes:
1. The pilot Phase IIA study for ALLOB requires 16 patients with symptomatic degenerative lumbar disc disease who need interbody fusion surgery.
2. ALLOB is intended to quicken the fusion process and decrease the failure rate of surgeries.
3. ALLOB, along with bioceramic granules, supplements an interbody cage.
4. The trial is underway in eight Belgium centers, in which eight patients have already undergone the procedure without any safety complications.
5. Bone Therapeutics is also conducting a study with ALLOB for treating failed spinal fusions, which will be the first minimally invasive revision spinal surgery using a bone cell therapy product.
More article on spine:
Primary care physicians lead in opioid prescriptions — 5 takeaways
Hyperbaric oxygen therapy can treat iatrogenic spine surgery infection — 6 key facts
Stanford Healthcare unveils new neuroscience center, integrating care: 5 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.